Supporting Patients In Cardiff

The VICTOR trial is a groundbreaking clinical trial available at TAP Centres across the UK, comparing a combination of two targeted drugs to traditional chemotherapy. This trial, specifically designed for AML patients aged 60 and over, offered a less toxic and more manageable treatment option.

A Phase 2 randomised trial for adults with Richter’s syndrome, a rare and aggressive form of lymphoma. The STELLAR trial is the first randomised trial for Richter’s syndrome in the UK, and it demonstrates the nation’s growing ability to run trials in rare diseases. The study also includes crucial translational research that will help tailor future therapies.

One of the TAP Network’s highest recruiting studies, AMMO trial tests a new drug in treating and extending the lives of patients with a rare bone marrow cancer, where treatment options are very limited. The treatment can be taken orally at home, making it much more convenient for patients. The trial has just concluded and results are expected to be published at the end of 2025.

Focused on patients with Myelofibrosis, the Fedora trial is tackling a critical area of unmet need, gathering information about whether a combination of treatments is tolerated, and whether it provides a therapeutic benefit to patients. The FEDORA Trial has now completed recruitment, with results expected to be published soon.